Advertisement

TheBodyPRO.com Covers IAS 2015

News

WHO 2015 Guidelines to Recommend Treatment for All HIV-Positive People

July 19, 2015

On 18 July 2015, at the IAS 2015 pre-conference UN 90-90-90 Target workshop: lessons from the field, Gottfried Hirnschall, Director of HIV Department at World Health Organization (WHO) provided a "sneak preview" of the in-the-process-of-being-updated 2015 consolidated guidelines.

The headline is: following the START results, WHO will recommend ART for everyone with HIV.

Also important is that dolutegravir and efavirenz 400 mg will be recommended as alternatives first-line options to using efavirenz 600 mg.


Comment

This is good news.

Expect more sneak previews of the guidelines -- details are promised at IAS.


Reference

Hirnschall G. WHO Global HIV Guidelines: How innovations in policy and implementation can pave the way to achieving 90-90-90. UN 90-90-90 Target workshop: lessons from the field.18 July 2015. Vancouver, BC, Canada.

www.treatmentaspreventionworkshop.org




This article was provided by HIV i-Base. It is a part of the publication HIV Treatment Bulletin. Visit HIV i-Base's website to find out more about their activities, publications and services.
 


No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:


Please note: Knowledge about HIV changes rapidly. Note the date of this summary's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this summary. For a complete listing of our most recent conference coverage, click here.

Advertisement

The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.